

A formal enantioselective synthesis of (+)-dodoneine via cyclic sulfate methodology

Srinivasu V.N. Vuppalapati, Siddamal R. Putapatri, and Srinivas Kantevari*

Organic Chemistry Division-II, Indian Institute of Chemical Technology, Hyderabad-500007,
INDIA

E-mail: kantevari@yahoo.com, kantevari@gmail.com


Abstract

An enantioselective formal synthesis of (+)-dodoneine is described using the Sharpless asymmetric dihydroxylation and regioselective nucleophilic opening of cyclic sulfate as the key steps.

Keywords: Sharpless asymmetric dihydroxylation, dodoneine, cyclic sulfate methodology, enantioselective synthesis

Introduction

Dodoneine **1**, [(R)-6-[(S)-2-hydroxy-4-(4-hydroxyphenyl)butyl]-5,6-dihydropyran-2-one], is a recently isolated α,β -unsaturated δ -lactone from the methanolic extract of a plant hemi parasite, *Tapinanthus dodoneifolius* DC Danser (also known as African mistletoe) found on a sheanut tree in Loumbila, West Africa.¹ The structure of **1** was determined from spectroscopic and X-ray crystallographic analysis of the camphorsulphonate derivative of dodoneine.




The compound (+)-Dodoneine **1** exhibited relaxing effect on precontracted rat aortic rings. The unique as well as challenging structural feature of this class of compounds along with their potential biological activity has aroused great interest among synthetic organic and medicinal chemists.²

The synthesis approaches described till now in the literature for dodoneine **1** involve 1) enantioselective addition of allyl metal reagents to aldehydes, followed by Grubbs ring closing metathesis³ 2) Horner-Wadsworth-Emmons olefination and Crimmins aldol approach⁴ and 3) Sharpless asymmetric epoxidation followed by 1,3-syn diastereoselective reduction and Grubbs ring closing metathesis.⁵ As part of our research work aimed at developing enantioselective syntheses of naturally occurring lactones, the Sharpless asymmetric dihydroxylation and subsequent transformation of the diols formed via cyclic sulfites/ sulfates were envisaged as powerful tools offering considerable opportunities for synthetic manipulations.⁶ Herein we report a new and highly enantioselective formal synthesis of (+)-dodoneine employing the Sharpless asymmetric dihydroxylation as the source of chirality.

Results and Discussion

Our approach for the synthesis of (+)-dodoneine was envisioned via the retrosynthetic route shown in Scheme 1.



Scheme 1. Retrosynthetic route to (+)-dodoneine.

The key intermediate aldehyde **2** was visualized as an ultimate precursor for the target molecule, which could be obtained from the hydride opening of cyclic sulfate **3** and subsequent hydrolysis. The cyclic sulfate **3** could be derived from commercially available *p*-hydroxy benzaldehyde **4** through series of reactions comprising double 2C Wittig olefinations and Sharpless asymmetric dihydroxylation. The salient feature of our synthetic strategy was on the presumption that regioselective nucleophilic opening of cyclic sulfate would occur at the α -carbon. The detailed route for the synthesis of aldehyde **2** with reagents and reaction conditions is outlined in Scheme 2.

furnished α , β -unsaturated ester **7** in good yields (91%). The dihydroxylation of *trans* olefin ester **7** with AD-mix- α , methane sulfonamide in *tert*-BuOH-H₂O (1:1) under the Sharpless asymmetric dihydroxylation reaction conditions gave diol **8** in 85% yield and 96% ee (from ¹H NMR analysis of its diacetate using Eu(III) chiral shift reagent). Sharpless and co-workers have also observed^{6a,7} that vicinal diol cyclic sulfates are “like epoxides only more reactive”. With this clue, the diol **8** was treated with thionyl chloride in the presence of triethyl amine in dichloromethane at 0 °C to give isomeric cyclic sulfite **9** in 94% yield. Ruthenium chloride-sodium periodate oxidation of sulfite **9** gave cyclic sulfate **3** in 92% yield. The essential feature of our synthetic strategy shown in the Scheme 2 was observed on the presumption that the nucleophilic opening of the cyclic sulfate would occur in the regiospecific manner at the α -position. Reduction of cyclic sulfates to mono alcohols with sodium borohydride in dimethyl acetamide was originally recommended.^{7a} The intermediate sulfate esters were then hydrolyzed in a 20% aqueous H₂SO₄-ether system. Alternatively, hydrolysis could be affected with a catalytic amount of concentrated sulfuric acid and 0.5-1.0 equiv of water in THF.⁸

We have observed that, hydrolysis (with catalytic amount of sulfuric acid and water) of intermediate sulfate ester, obtained from cyclic sulfate **3** after treatment with sodium borohydride in DMF at 25 °C, was sluggish and gave the desired product alcohol **10** in low yields (<10%). Conducting both the stages of reaction at 0 °C for longer hours (2-3 h each) improved the formation of alcohol **10** (52% yield), but α , β -unsaturated ester **7** was also obtained as side product in substantial amount (~35%). After series of experiments, we have established that treatment of cyclic sulfate **3** with sodium borohydride in DMF for 15 minutes at 0 °C, followed by hydrolysis with catalytic amount of concentrated sulfuric acid and 0.35 equiv of water in THF at 0 °C for 20 min afforded the desired alcohol **10** in quantitative yield (90%). The choice of reaction conditions (reaction temperature and time) is crucial for the successful yield of the desired product alcohol **10**.

Next, the secondary hydroxyl group of compound **10** was protected (TBS-Cl, imidazole, CH₂Cl₂, overnight) to furnish TBS protected ester **11** in 95% yield. The ester **11** was then subjected to reduction with DIBAL-H in dichloromethane at -78 °C to yield aldehyde **2** in 88% yield. Absolute stereo chemistry of the product aldehyde (*S*)-**2** was ascertained by comparing all the analytical (specific rotation, $[\alpha]_D^{25} = +5.54$ (c 2.1, CHCl₃), Lit^{3c} $[\alpha]_D^{25} = +5.57$) and ¹H and ¹³C NMR spectral data with recently reported literature values.^{3c}

Natural product (+)-Dodoneine **1** was finally obtained from aldehyde (*S*)-**2** by following a well described^{3,5} reaction sequence comprising asymmetric allylation with allyl magnesium bromide, acylation with acryloyl chloride and Grubbs ring closing metathesis.

In conclusion, a formal synthesis of (+)-dodoneine **1** has been accomplished by Sharpless asymmetric dihydroxylation and regioselective nucleophilic opening of cyclic sulfate. The optimum conditions for the key steps, nucleophilic opening of cyclic sulfate **3** with sodium borohydride in regioselective manner at the α -position (0 °C / 15 min) and subsequent hydrolysis of sulfate ester (0 °C / 20 min) is ascertained after series of experimentations. Further application of

this cyclic sulfate methodology to the synthesis of biologically active compounds for structure-activity studies is currently underway in our laboratory.

Experimental Section

General. All the reactions were monitored by TLC (recoated silica plates and visualizing under UV light). Air-sensitive reagents were transferred by syringe or double-ended needle. Evaporation of solvents was performed at reduced pressure on a Buchi rotary evaporator. ^1H and ^{13}C NMR spectra of samples in CDCl_3 were recorded on Bruker UXMNMR FT-300 MHz (Avance) spectrometer and Varian FT-500MHz (Inova). Chemical shift reported are relative to an internal standard TMS ($\delta=0.0$). Mass spectra were recorded in EI conditions at 70 eV on an LC-MSD (Agilent technologies) spectrometer. All high-resolution spectra were recorded on QSTAR XL hybrid MS/MS system (Applied Biosystems/ MDS sciex, Foster City, USA), equipped with an ESI source (IICT, Hyderabad). Column chromatography was performed on silica gel (60-120 mesh) supplied by Acme Chemical Co., India. TLC was performed on Merck 60 F-254 silica gel plates. Optical rotations were measured with JASCO DIP-370 Polarimeter at 25 $^\circ\text{C}$. Commercially available anhydrous solvents CH_2Cl_2 , THF, and EtOAc were used as such without further purification.

4-(*tert*-Butyldimethylsilyloxy)benzaldehyde

To the stirred solution of *p*-hydroxybenzaldehyde **4** (6.0 g, 49.18 mmol) in anhydrous CH_2Cl_2 (35 mL), imidazole (5.0 g, 73.77 mmol) followed by *tert*-butyldimethylsilyl chloride (8.89 g, 59.01 mmol) were added at 0 $^\circ\text{C}$ under N_2 . After stirring the reaction mixture for 1.5 h, at 25 $^\circ\text{C}$, it was quenched with a saturated aqueous solution of NH_4Cl and extracted with CH_2Cl_2 (6 x 30 mL). The combined organic extracts were washed with brine, dried over anhydrous Na_2SO_4 and concentrated in vacuum. The residue was purified by flash column chromatography over silica gel (ethyl acetate/hexane, 5:95) afforded 4-(*tert*-butyldimethylsilyloxy)benzaldehyde (11.12 g, 96%) as colorless liquid. IR (neat): 2934, 2858, 1697, 1598, 1508, 1272, 1156, 908 cm^{-1} .

^1H NMR (300 MHz, CDCl_3): δ 9.86 (s, 1H), 7.74 (d, $J=7.8\text{Hz}$, 2H), 6.89 (d, $J=8.7\text{Hz}$, 2H), 0.99 (s, 9H), 0.24 (s, 6H). ^{13}C NMR (75MHz, CDCl_3): δ 189.8, 161.2, 131.8, 120.4, 96.2, 25.7, 18.4, -4.1. ESI-MS: m/z 259 $[\text{M}+\text{Na}]^+$. HRMS (ESI) $[\text{M}+\text{Na}]^+$ m/z Calcd for $\text{C}_{13}\text{H}_{20}\text{O}_2\text{NaSi}$: 259.1130; found: 259.1125.

(*E*)-Ethyl 3-[4-(*tert*-butyldimethylsilyloxy)phenyl] acrylate (5**).** Ethyl (triphenylphosphonylidene)acetate (18.2 g, 54.0 mmol) was added to a stirred solution of 4-(*tert*-butyldimethylsilyloxy)benzaldehyde (8.5 g, 36.0 mmol) in dry benzene (80 mL). The reaction mixture was refluxed for 6.5 h, and concentrated in vacuum. Crude residue thus obtained was purified by column chromatography (ethyl acetate/hexane 1:9) afforded (*E*)-ethyl 3-(4-(*tert*-butyldimethylsilyloxy)phenyl) acrylate **5** (10.13 g, 92%) as color less liquid.

IR (neat): 2934, 1713, 1601, 1509, 1263, 1167, 912 cm^{-1} . ^1H NMR (300 MHz, CDCl_3): δ 7.55 (d, $J=15.8\text{Hz}$, 1H), 7.37 (d, $J=8.3\text{Hz}$, 2H), 6.77 (d, $J=8.3\text{Hz}$, 2H), 6.21 (d, $J=15.8\text{Hz}$, 1H), 4.21 (q, $J=7.5\text{Hz}$, 2H), 1.33 (t, $J=7.5\text{Hz}$, 3H), 0.98 (s, 9H), 0.21 (s, 6H). ESI-MS: m/z 329 $[\text{M}+\text{Na}]^+$. HRMS (ESI) $[\text{M}+\text{Na}]^+ m/z$ Calcd for $\text{C}_{17}\text{H}_{26}\text{O}_3\text{NaSi}$: 329.1548; found; 329.1544.

3-(4-(*tert*-Butyldimethylsilyloxy)phenyl)propionic acid ethyl ester

A mixture of **5** (8.2 g, 26.77 mmol), 10% Pd/C in ethyl acetate (75 mL) was stirred at 25 $^\circ\text{C}$ under H_2 (1 atm) for 12 h. After completion of reaction (monitored by TLC), it was filtered through a celite (ethyl acetate as eluent) and the solvent evaporated under vacuum to afford 3-(4-(*tert*-butyldimethylsilyloxy)phenyl)propionic acid ethyl ester (7.50 g, 92%) as colorless liquid.

IR (neat): 2934, 1736, 1510, 1258, 1169, 916 cm^{-1} . ^1H NMR (500 MHz, CDCl_3): δ 6.99 (d, $J=7.8\text{Hz}$, 2H), 6.68 (d, $J=7.8\text{Hz}$, 2H), 4.08 (q, $J=6.8\text{Hz}$, 2H), 2.84 (t, $J=7.8\text{Hz}$, 2H), 2.53 (t, $J=7.8\text{Hz}$, 2H), 1.22 (t, $J=6.8\text{Hz}$, 3H), 0.97 (s, 9H), 0.17 (s, 6H). ESI-MS: m/z 309 $[\text{M}+\text{H}]^+$. HRMS (ESI) $[\text{M}+\text{Na}]^+ m/z$ Calcd for $\text{C}_{17}\text{H}_{28}\text{O}_3\text{NaSi}$: 331.1705; found; 331.1716.

3-(4-(*tert*-Butyldimethylsilyloxy)phenyl)propan-1-ol (6). To a stirred suspension of LiAlH_4 (1.35 g, 35.55 mmol) in dry THF (30 mL), was added drop wise 3-(4-(*tert*-butyldimethylsilyloxy)phenyl)propionic acid ethyl ester (7.3 g, 23.70 mmol) in dry THF (40 mL) at 0 $^\circ\text{C}$. After 1.5 h at 0 $^\circ\text{C}$, it was quenched with the addition of saturated aqueous Na_2SO_4 solution, filtered through a celite pad (hot ethyl acetate as eluent). Residue obtained after evaporating the combined solvent under vacuum was purified by column chromatography (ethyl acetate/ hexane 15:85) to give 3-(4-(*tert*-butyldimethylsilyloxy)phenyl) propan-1-ol, **6** (5.73 g, 91%) as colorless liquid. IR (neat): 3416, 2932, 1508, 1254, 1041, 914 cm^{-1} . ^1H NMR (500MHz, CDCl_3): δ 6.98 (d, $J=7.8\text{Hz}$, 2H), 6.68 (d, $J=7.8\text{Hz}$, 2H), 3.65-3.60 (m, 2H), 2.62 (t, $J=7.8\text{Hz}$, 2H), 1.86-1.80 (m, 2H), 0.97 (s, 9H), 0.17 (s, 6H). ^{13}C NMR (75MHz, CDCl_3): δ 153.6, 134.3, 129.1, 119.8, 62.3, 34.3, 31.2, 25.6, 18.1.

3-(4-(*tert*-Butyldimethylsilyloxy)phenyl)propanal

To a solution of oxalyl chloride (16.9 mmol, 1.41 mL) in dry dichloromethane (20 mL) at -78 $^\circ\text{C}$, DMSO (3.2 mL, 45.08 mmol) was added dropwise with stirring under nitrogen atmosphere. After 15 min, compound **6** (3 g, 11.27 mmol) was added into the reaction mixture and subsequently after stirring for 30 min at -78 $^\circ\text{C}$, Et_3N (56.35mmol, 7.8 mL) was added and the mixture was stirred for another 0.5 h at -78 $^\circ\text{C}$ and then for 0.5 h at 0 $^\circ\text{C}$. The reaction mixture was quenched with saturated NH_4Cl solution (40 mL) at 0 $^\circ\text{C}$ and extracted with EtOAc (5 x 30 mL). The combined organic extracts were washed with brine, dried over anhydrous Na_2SO_4 and concentrated in vacuum. The 3-(4-(*tert*-butyldimethylsilyloxy)phenyl)propanal thus obtained after flash column chromatography (2.79 g, 94%) was used directly for further reaction.

^1H NMR (300MHz, CDCl_3): δ 9.78 (s, 1H), 6.98 (d, $J=8.7\text{Hz}$, 2H), 6.68 (d, $J=8.7\text{Hz}$, 2H), 2.86 (t, $J=7.8\text{Hz}$, 2H), 2.71 (t, $J=6.8\text{Hz}$, 2H), 0.97 (s, 9H), 0.17 (s, 6H).

(*E*)-Ethyl 5-(4-(*tert*-butyldimethylsilyloxy)phenyl) pent-2-enoate (7). A solution of 3-(4-(*tert*-butyldimethylsilyloxy) phenyl) propanal (2.0 g, 7.57 mmol) and ethyl (triphenyl phosphor

nylidene) acetate (3.84 g, 11.36 mmol) in benzene (20 mL), was refluxed for 8 h. After completion of reaction (by TLC), it was concentrated in vacuum and the residue was purified by column chromatography (ethyl acetate/ hexane 5:95) to afford **7** (2.30 g, 91%) as a colorless liquid. IR (neat): 2932, 1721, 1509, 1259, 1192, 915 cm^{-1} . ^1H NMR (500 MHz, CDCl_3): δ 6.96 (d, J = 7.8Hz, 2H), 6.91 (d, J = 15.6 Hz, 1H), 6.89 (d, J = 7.8Hz, 2H), 5.76 (d, J = 15.6Hz, 1H), 4.14 (q, J = 6.8Hz, 2H), 2.69 (t, J = 7.8Hz, 2H), 2.46 (q, J = 7.8Hz, 2H), 1.28 (t, J = 6.8Hz, 3H), 0.97 (s, 9H), 0.17 (s, 6H). ^{13}C NMR (75 MHz, CDCl_3): δ 166.5, 153.8, 148.1, 133.4, 129.1, 121.6, 119.9, 60.0, 34.0, 33.4, 25.4, 18.1, 14.1, -4.5. ESI-MS: m/z 335 $[\text{M}+\text{H}]^+$. HRMS (ESI) $[\text{M}+\text{Na}]^+$ m/z Calcd for $\text{C}_{19}\text{H}_{30}\text{O}_3\text{NaSi}$: 357.1861; found: 357.1856.

(2R,3S)-Ethyl 5-(4-(tert-butyldimethylsilyloxy)phenyl)-2,3-dihydroxypentanoate (8). To a solution of AD mix- α (4.2 g) in *t*-BuOH: H_2O (1:1, 20 mL), was added MeSO_2NH_2 (300 mg) and alkene **7** (1.0 g, 2.99 mmol) slowly at 0°C and the mixture was stirred overnight at the same temperature. After complete consumption of the starting material, sodium sulfite (4.5 g) was added and the solution was warmed to room temperature and stirred for 90 min. After which the reaction mixture was poured in water (10 ml) and several times with ethyl acetate (4x100 mL). Combined organic extracts were washed with brine (2 x 100 mL), dried over Na_2SO_4 and concentrated in vacuum. Crude residue was chromatographed over silica (ethyl acetate/hexane 30:70) afforded **8** (0.93 g, 85%) as colorless liquid. $[\alpha]_{\text{D}}^{25} = -7.0$ (c 1.0, CHCl_3). IR (neat): 3432, 2933, 2858, 1736, 1509, 1257, 1118, 916 cm^{-1} . ^1H NMR (300MHz, CDCl_3): δ 7.00 (d, J = 8.3Hz, 2H), 6.68 (d, J = 8.3Hz, 2H), 4.25 (q, J = 7.1Hz, 2H), 4.01-3.99 (m, 1H), 3.85- 3.77 (m, 1H), 3.01-2.95 (m, 1H), 2.79-2.57 (m, 2H), 1.92-1.79 (m, 3H), 1.31 (t, J = 7.1Hz, 3H), 0.97 (s, 9H), 0.17 (s, 6H). ^{13}C NMR (75MHz, CDCl_3): δ 173.4, 153.7, 134.0, 129.2, 119.9, 73.1, 71.7, 62.1, 35.5, 31.0, 25.6, 18.1, 14.1, -4.4. ESI-MS: m/z 391 $[\text{M}+\text{Na}]^+$. HRMS (ESI) $[\text{M}+\text{Na}]^+$ m/z Calcd for $\text{C}_{19}\text{H}_{32}\text{O}_5\text{NaSi}$: 391.1916; found: 391.1916.

Cyclic sulfite, 9. To a solution of the compound **8** (0.85 g, 2.30 mmol) in CH_2Cl_2 (20 mL) at 0°C , was added Et_3N (0.64 mL, 4.61mmol) followed by freshly distilled thionyl chloride (0.2 mL, 2.77 mmol) drop wise. It was stirred further for 45min at 0°C and then quenched by adding H_2O (20 mL). The phases were separated, aqueous phase was extracted with CH_2Cl_2 (3 x 50 mL), combined organic phases were dried with Na_2SO_4 and concentrated in vacuum. After flash column chromatography this cyclic sulfite **9** (0.89 g, 94%) was used for the next reaction.

Cyclic sulfate, 3. The cyclic sulfite **9** (0.70 g, 1.69 mmol) dissolved in CCl_4 (10 mL) and CH_3CN (10 mL) was cooled in an ice bath and cold H_2O (15 mL) followed by $\text{RuCl}_3\cdot\text{H}_2\text{O}$ (17 mg, 0.10 mmol) and NaIO_4 (0.72 g, 3.38mmol) were added at once. The reaction mixture was vigorously stirred at 0°C for 30 min, extracted with ether (3x50 mL); the organic layer was washed with brine, dried over Na_2SO_4 and concentrated in vacuum. The crude residue was purified by column chromatography to afford **3** (0.66 g, 92%) as violet color liquid. $[\alpha]_{\text{D}}^{25} = -46.2$ (c 1.0, CHCl_3).

IR (neat): 2933, 1768, 1510, 1398, 1259, 1209, 1018, 912 cm^{-1} . ^1H NMR (500 MHz, CDCl_3): δ 7.00 (d, J = 8.7Hz, 2H), 6.72 (d, J = 7.8Hz, 2H), 4.87-4.83 (m, 1H), 4.75 (d, J = 7.8Hz, 1H), 4.29 (q, J = 6.8Hz, 2H), 2.87-2.82 (m, 1H), 2.74-2.68 (m, 1H), 2.30-2.19 (m, 2H), 1.33 (t, J = 6.8Hz,

3H), 0.97 (s, 9H), 0.18 (s, 6H). ^{13}C NMR (75MHz, CDCl_3): δ = 164.5, 154.2, 131.4, 129.2, 120.2, 83.0, 79.6, 63.1, 34.7, 30.0, 25.5, 18.0, 13.8, -4.5. ESI-MS: m/z 453 $[\text{M}+\text{Na}]^+$. HRMS (ESI) $[\text{M}+\text{Na}]^+$ m/z Calcd for $\text{C}_{19}\text{H}_{30}\text{O}_7\text{NaSi}$: 453.1379; found: 453.1361.

(S)-Ethyl 5-(4-(tert-butyldimethylsilyloxy)phenyl)-3-hydroxypentanoate (10). To a stirred solution of cyclic sulfate **3** (0.30 g, 0.69 mmol) in dry DMF (5 mL) at 0 °C, was added NaBH_4 (52 mg, 1.39 mmol) under N_2 atm. After 15 min of stirring, solvent was removed under reduced pressure (0.2 mm Hg,) and the residue was suspended in dry THF (10 mL). At 0°C, conc. H_2SO_4 (35 μL) and H_2O (15 μL) were added slowly with stirring for another 20 min and excess sodium bicarbonate (200 mg) was added with stirring further for 20 min. Filtered through a celite pad (hot ethyl acetate as eluent), filtrate was concentrated under reduced pressure and the crude liquid was chromatographed (ethyl acetate/ hexane 20:80) to give (S)-ethyl5-(4-(tert-butyldimethylsilyloxy)phenyl)-3-hydroxypentanoate **10** (0.22 g, 90%) as a colorless liquid. $[\alpha]_{\text{D}}^{25}$ = -5.0 (c 1.0, CHCl_3). IR (neat): 3451, 2931, 2858, 1727, 1509, 1256, 1179, 915 cm^{-1} . ^1H NMR (500MHz, CDCl_3): δ 6.99 (d, J = 8.1Hz, 2H), 6.67 (d, J = 8.1Hz, 2H), 4.14 (q, J = 7.2Hz, 2H), 3.96-3.91 (m, 1H), 2.94 (d, J = 3.6Hz, 1H), 2.75-2.69 (m, 1H), 2.63-2.57 (m, 1H), 2.46-2.35 (m, 2H), 1.81-1.74 (m, 1H), 1.68-1.62 (m, 1H), 1.27 (d, J = 7.2Hz, 3H), 0.97 (s, 9H), 0.17 (s, 6H). ^{13}C NMR (75MHz, CDCl_3): δ 172.9, 153.6, 134.2, 129.1, 119.8, 67.1, 60.6, 41.2, 38.2, 30.8, 29.6, 25.6, 18.1, 14.1, -4.4.ESI-MS: m/z 353 $[\text{M}+\text{H}]^+$. HRMS (ESI) $[\text{M}+\text{Na}]^+$ m/z Calcd for $\text{C}_{19}\text{H}_{32}\text{O}_4\text{NaSi}$: 375.1967; found: 375.1981.

(S)-Ethyl 3-(tert-butyldimethylsilyloxy)-5-(4-(tert-butyldimethylsilyloxy)phenyl)pentanoate (11). To compound **10** (0.15 g, 0.42 mmol) in dry CH_2Cl_2 (5 mL), imidazole (86 mg, 1.27 mmol) followed by TBS-Cl (130 mg, 0.85 mmol) were added at 0 °C under N_2 . After stirring the reaction mixture over night, it was quenched with a saturated solution of NH_4Cl (3 mL) and extracted with CH_2Cl_2 (6 x 25 mL). The combined organic extracts were washed with brine, dried over anhydrous Na_2SO_4 and concentrated in vacuum. The crude residue was flash chromatographed (ethyl acetate/hexane 5:95) to afford (S)-ethyl 3-(tert-butyldimethylsilyloxy)-5-(4-(tert-butyl dimethylsilyloxy)phenyl)pentanoate **11** (0.18g, 95%) as colorless liquid. $[\alpha]_{\text{D}}^{25}$ = +10.6 (c 1.0, CHCl_3).IR (neat): 2932, 2858, 1737, 1509, 1256, 1091, 916 cm^{-1} . ^1H NMR (300MHz, CDCl_3): δ 7.00 (d, J = 8.3Hz, 2H), 6.73 (d, J = 8.3Hz, 2H), 4.20-4.08 (m, 3H), 2.62-2.52 (m, 2H), 2.47 (t, J = 6.7Hz, 2H), 1.82-1.73 (m, 2H), 1.25 (t, J = 6.7Hz, 3H), 0.97 (s, 9H), 0.88 (s, 9H), 0.17 (s, 6H), 0.06 (s, 3H), 0.03 (s, 3H).

^{13}C NMR (75MHz, CDCl_3): δ 171.7, 153.5, 134.6, 129.0, 119.8, 68.9, 60.3, 42.5, 39.4, 30.4, 25.7, 25.6, 18.1, 14.1, -4.8, -4.5, -4.4.ESI-MS: m/z 467 $[\text{M}+\text{H}]^+$. HRMS (ESI) $[\text{M}+\text{Na}]^+$ m/z Calcd for $\text{C}_{25}\text{H}_{46}\text{O}_4\text{NaSi}_2$: 489.2832; found: 489.2853.

(S)-3-(tert-butyldimethylsilyloxy)-5-(4-(tert-butyl dimethylsilyloxy) phenyl)pentanal (2). To a solution of (S)-ethyl 3-(tert-butyldimethylsilyloxy)-5-(4-(tert-butyldimethylsilyloxy)phenyl) pentanoate **11** (0.1 g, 0.21 mmol) in dry CH_2Cl_2 (2 mL), DIBAL-H (1.0M, 0.23 mL, 0.23 mmol) was added drop wise at -78 °C and stirred for 10 min. The reaction mixture was quenched with saturated aqueous sodium potassium tartrate (1 mL) at -78 °C, stirred for 20 min and then brought to room temperature. The organic layer was separated and aqueous layer was extracted

with EtOAc (4x10 mL), combined organic extracts were dried over anhydrous Na₂SO₄ and concentrated in vacuum. The crude residue thus obtained was purified by column chromatography (ethyl acetate/hexane 10:90) to afford (*S*)-3-(*tert*-butyldimethylsilyloxy)-5-(4-(*tert*-butyldimethyl silyloxy)phenyl)pentanal **2** (0.078g, 88%) as a colorless liquid. $[\alpha]_D^{25} = +5.54$ (c 2.1, CHCl₃); Lit^{3c} $[\alpha]_D^{25} = +5.57$. ¹H NMR (500MHz, CDCl₃): δ 9.80 (t, *J*= 1.9 Hz, 1H), 6.99 (d, *J*= 8.7Hz, 2H), 6.73 (d, *J*= 8.7Hz, 2H), 4.22 (q, *J*= 5.8Hz, 1H), 2.60-2.55 (m, 4H), 1.85-1.80 (m, 2H), 0.98 (s, 9H), 0.89 (s, 9H), 0.18 (s, 6H), 0.07 (s, 3H), 0.04 (s, 3H). ¹³C NMR (75MHz, CDCl₃): δ 202.0, 153.7, 134.2, 129.0, 119.9, 67.7, 50.7, 39.6, 30.6, 25.7, 18.1, 17.9, -4.4, -4.6.

Acknowledgments

We thank Dr. J. S. Yadav, Director IICT, and Dr. V.V. Narayana Reddy, Head, Organic Chemistry Division- II for their constant encouragement and support. S.V.N.V. (SRF) and S.R.P. (JRF) thank CSIR, New Delhi for the award of fellowships.

Supplementary Material

Copies of ¹H NMR and ¹³C NMR of compounds **2**, **3**, **7**, **8**, **10** and **11**.

References

1. Ouedraogo, M.; Carreyre, H.; Vandelrouck, C.; Bescound, J.; Raymond, G.; Guissou, I.-P.; Cognard, C.; Becq, F.; Potreau, D.; Cousson, A.; Marrot, J.; Coustard, J.-M. *J. Nat. Prod.* **2007**, *70*, 2006.
2. (a) Jodynis-Liebert, J.; Murias, M.; Bloszyk, E. *Planta Med.* **2000**, *66*, 199. (b) Nicolaou, K. C.; Rodriguez, R. M.; Mitchell, H. J.; Suzuki, H.; Fylaktakidou, K. C.; Baudoin, O.; van Delft, F. L. *Chem. Eur. J.* **2000**, *6*, 3095. (c) Carda, M.; Gonzalez, F.; Castillo, E.; Rodriguez, S.; Marco, J. A. *Eur. J. Org. Chem.* **2002**, 2649. (d) Murga, J.; Falomir, E.; Garcia-Fortanet, J.; Carda, M.; Marco, J. A. *Org. Lett.* **2002**, *4*, 3447. (e) Bouzbouz, S.; Cossy, J. *Org. Lett.* **2003**, *5*, 1995. (f) Sabitha, G.; Bhaskar, V.; Reddy, S. S. S.; Yadav, J. S. *Tetrahedron* **2008**, *64*, 10207.
3. (a) Alvarez-Bercedo, P.; Falomir, E.; Murga, J.; Carda, M.; Marco, J. A. *Eur. J. Org. Chem.* **2008**, 4015. (b) Dittoo, A.; Bellosta, V.; Cossy, J. *Synlett* **2008**, *16*, 2459. (c) Rauniyar, V.; Hall, D. G. *J. Org. Chem.* **2009**, *74*, 4236.
4. Srihari, P.; Rajender, G.; Rao, R.S.; Yadav, J. S. *Tetrahedron Lett.* **2008**, *49*, 5590.

5. Das, B.; Suneel, K.; Satyalakshmi, G.; Kumar, D. N. *Tetrahedron: Asymmetry* **2009**, *20*, 13, 1536.
6. (a) Byun, H-S.; He, L.; Bittman R. *Tetrahedron* **2000**, *56*, 7051. (b) Qin, D-G.; Zha, H-Y.; Yao, Z-J. *J. Org. Chem.* **2002**, *67*, 1038. (c) Fernandes, R. A.; Kumar, P. *Eur. J. Org. Chem.* **2002**, 2921. (d) Gupta, P.; Naidu, S. V.; Kumar, P. *Tetrahedron Lett.* 2004, *45*, 9641. (e) Jagdale, A. R.; Reddy, Sudalai, A. *Org. Lett.* **2009**, *11*, 803.
7. (a) Gao, Y.; Sharpless, K. B. *J. Am. Chem. Soc.*, **1988**, *110*, 7538. (b) Lohray, B. B. *Synthesis*, **1992**, 1035.
8. Kim, B. M.; Sharpless, K. B. *Tetrahedron Lett.* **1989**, *6*, 655.